Previous 10 | Next 10 |
2024-04-05 14:55:10 ET More on mid-day movers & stock 22nd Century Group, Inc. (XXII) Q4 2023 Earnings Call Transcript Grindrod Shipping: Favorable Outlook, M&A Completion, And Very Cheap Grindrod Shipping: When A Young Fleet And Healthy Financials Are Not En...
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update PR Newswire CAMBRIDGE, Mass. , April 5, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegene...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial PR Newswire PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS Standard ALS Measure ALSFR...
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire CAMBRIDGE, Mass. , Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, tod...
HERZLIYA, ISRAEL / ACCESSWIRE / January 30, 2024 / Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and ultimately death within two to five years f...
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts PR Newswire End of Phase 2 meeting with the FDA and EMA expected in Q2 2024 and several b...
2023-12-27 17:02:59 ET More on NeuroSense Therapeutics NeuroSense: A Hold Ahead Of Phase 2b ALS Data NeuroSense ALS candidate meets key study goals NeuroSense ends equity offering, says it's fully funded into Q2 2024 For further details see: NeuroSense Th...
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement PR Newswire This notification has no immediate effect on the listing or trading of NeuroSense's ordinary shares on the Nasdaq Capital Market CAMBRIDG...
News, Short Squeeze, Breakout and More Instantly...
NeuroSense Therapeutics Ltd. Company Name:
NRSN Stock Symbol:
NASDAQ Market:
NeuroSense Therapeutics Ltd. Website:
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression PR Newswire NeuroSense to submit the 12-month data to FDA to discuss path forward CAMBRIDGE, Mass. ...
NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug PR Newswire Disease progression was slowed by 36% (p=...
NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results PR Newswire Following positive 6-month clinical outcomes from phase 2b (PARADIGM) clinical trial, Company expects additional biomarker and 12-month clinical in the near term ...